GlassScriptPhysician profile
Viktoria Kaplan
NPI 1669422457
$57,886.20
in general payments reported to CMS, 2019-2025
58 companies · $17K in 2025
The $17K reported for 2025 was more than what 92% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $446 · 2021: $6,771 · 2022: $1,582 · 2023: $2,356 · 2024: $3,032 · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Food and Beverage: $8,092 · Consulting Fee: $3,043 · Travel and Lodging: $409 · Education: $1.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,225.00 |
| Food and Beverage | $8,092.04 |
| Consulting Fee | $3,043.00 |
| Travel and Lodging | $409.00 |
| Education | $1.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $31,234.50 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Genentech USA, INC. | $10,009.76 | 2019-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Novartis Pharmaceuticals Corporation | $4,677.89 | 2019-2025 | |
| Tg Therapeutics, INC. | $2,347.18 | 2022-2025 | |
| Emd Serono, INC. | $1,563.78 | 2019-2025 | Mavenclad |
| Abbvie INC. | $1,473.85 | 2021-2025 | |
| Genzyme Corporation | $820.32 | 2019-2025 | |
| Amgen INC. | $545.09 | 2020-2025 | Uplizna |
| Celgene Corporation | $481.64 | 2019-2025 | Zeposia |
| Argenx US, INC. | $410.12 | 2023-2025 | Vyvgart Hytrulo |
| Ucb, INC. | $398.20 | 2019-2025 | Rystiggo, Zilbrysq, Briviact |
| Sk Life Science, INC. | $359.08 | 2020-2025 | Xcopri |
| Teva Pharmaceuticals USA, INC. | $268.88 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $259.87 | 2019-2025 | Ultomiris, Soliris |
| Sunovion Pharmaceuticals INC. | $225.37 | 2019 |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Viktoria Kaplan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.